Impact of adalimumab on rheumatoid arthritis (RA) outcomes: Comparison of an open-label extension study and a registry-based control group

被引：0
|
作者：
Halpern, M. T. [1 ]
Citaldi, M. [2 ]
Kvien, T. [3 ]
机构：
[1] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA
[2] Abbott Labs, Global Hlth Econ & Outcomes Res, Abbott Pk, IL 60064 USA
[3] Diakonjemmet Hosp, Dept Rheumatol, Oslo, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [1] Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group
    Halpern, M. T.
    Cifaldi, M. A.
    Kvien, T. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) : 930 - 937
  • [2] EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSION OF A PHASE 3 MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)
    Burmester, G. R.
    Fiore, S.
    Hu, C-C
    van Hoogstraten, H.
    Lee, Bong E.
    Genovese, M. C.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 21 - 21
  • [3] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Martincova, Renata
    Burmester, Gerd R.
    RHEUMATOLOGY, 2017, 56 : 139 - 139
  • [4] OPEN-LABEL TREATMENT OF RHEUMATOID-ARTHRITIS (RA) - EFFICACY AND TOLERABILITY OF NABUMETONE
    SPREKELER, R
    BRITISH JOURNAL OF RHEUMATOLOGY, 1992, 31 : 164 - 164
  • [5] A PROSPECTIVE OPEN-LABEL SINGLE CENTER STUDY OF ADALIMUMAB IN BEHCET ARTHRITIS
    Braun-Moscovici, Y.
    Tavor, Y.
    Markovits, D.
    Naffaa, M.
    Toledano, K.
    Rozin, A.
    Beshara-Garzoz, R.
    Nahir, M. A.
    Balbir-Gurman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1103 - 1103
  • [6] Combination cyclosporine(CsA)/methotrexate(MTX)for severe rheumatoid arthritis (RA): An open-label 2-year extension study.
    Yocum, DE
    Pincus, T
    Stein, CM
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S243 - S243
  • [7] Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients
    Genovese, Mark
    Fay, Jonathan
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    van Hoogstraten, Hubert
    Graham, Neil
    Boddy, Alex
    Simon, Abraham
    Martincova, Renata
    Burmester, Gerd
    Fiore, Stefano
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 895 - 896
  • [8] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Genovese, M. C.
    Fay, J.
    Beyer, D.
    Iglesias-Rodriguez, M.
    Simon, A.
    Martincova, R.
    Burmester, G. R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
  • [9] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Simon, J-Abraham
    Martincova, Renata
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] Rheumatoid arthritis treatment with weekly leflunomide:: An open-label study
    Jaimes-Hernández, J
    Robles-San Román, M
    Suárez-Otero, R
    Dávalos-Zugasti, ME
    Arroyo-Borrego, S
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (02) : 235 - 237
12345